Chinese Copycats: T...
Health Care: Drugs
Santarus Inc. (SNTS: NASDAQ)
$22.28 -0.02 | -0.09%
05/22/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 18.56M | 4.67M | -18.47M | 32.12M |
| Operating Gains/Losses | 146.00K | -3.00K | 0.00 | -48.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -10.75M | -13.12M | 9.10M | -2.89M |
| (Increase) Decrease in Inventories | -4.77M | 1.67M | 2.31M | -106.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 13.00M | 3.42M | -29.67M | 5.57M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 5.80M | -27.00K | 316.00K | -4.28M |
| Other Non-Cash Items | 10.43M | 5.36M | 8.42M | 4.57M |
| Net Cash From Continuing Operations | 35.75M | 7.97M | -28.02M | 37.00M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 35.75M | 7.97M | -28.02M | 37.00M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 15.37M | 14.82M | 17.79M | 10.03M |
| Purchases of Property, Plant & Equipment | -796.00K | -223.00K | -5.31M | -274.00K |
| Acquisitions | -2.52M | -12.26M | -842.00K | 0.00 |
| Purchases of Short-Term Investments | -55.03M | -14.83M | -17.81M | -11.88M |
| Other Cash from Investing Activities | -950.00K | 0.00 | 0.00 | 450.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -43.93M | -12.49M | -2.32M | -1.67M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 3.88M | 2.07M | 906.00K | 912.00K |
| Repayment of Long-Term Debt | -175.00K | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 3.70M | 2.07M | 906.00K | 912.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -4.47M | -2.45M | -29.44M | 36.24M |
Portfolios with SNTS
- Portfolio NameUser Type
- UserWatch
- ContributorStocks Under-$10 Setting Up...
- ContributorDrugs Facing FDA Approval i...
- ContributorBreakout Stocks Of The Week...
- UserRogers BioMed
- ContributorStocks At New 52-Week Highs...
- UserJust Learning ao926
- UserJust Learning
- ContributorDollar Store
- Userbetterlatethannever
Latest SNTS Headlines from TheStreet
- Dow Closes at Record High 03.05.13 | 04:03 pm
- Cramer's 'Mad Money' Recap: The Bullish Facts 01.17.13 | 08:01 pm
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
- Top Insider Trades: LMCA, ST, SNTS, BEAV 12.20.12 | 01:12 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 5 Under-$10 Stocks Set to Trade Higher in November 11.08.12 | 01:11 pm
- Santarus Inc. Stock Upgraded (SNTS) 08.27.12 | 05:08 am
- Santarus' CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.07.12 | 09:08 pm
- Santarus Reaches New 52-Week High (SNTS) 06.12.12 | 04:06 pm
- Santarus Stock Falls On Unusually High Volume (SNTS) 05.30.12 | 04:05 pm
Press Releases for SNTS
- Santarus Announces Publication In Gut Of Results From UCERIS (budesonide) European Pivotal Clinical Study - Business Wire 03.18.13 | 07:03 am
- Santarus And VeroScience Announce Publication Of AACE Expert Panel Recommendations For CYCLOSET® (bromocriptine Mesylate) For The Management Of Type 2 Diabetes - Business Wire 03.06.13 | 07:03 am
- Santarus Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.04.13 | 04:03 pm
- Santarus To Present At March Investment Conferences - Business Wire 02.27.13 | 07:02 am
- Santarus To Hold Fourth Quarter And Full Year 2012 Financial Results Conference Call On March 4 - Business Wire 02.19.13 | 07:02 am
- Santarus Announces Commercial Launch Of UCERIS (budesonide) Extended Release Tablets - Business Wire 02.14.13 | 07:02 am
- Santarus To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 07:02 am
- Santarus And VeroScience Announce Publication Of Positive Data From Pivotal CYCLOSET® (bromocriptine Mesylate) Efficacy Study - Business Wire 01.23.13 | 07:01 am
- Santarus Receives FDA Approval Of UCERIS (Budesonide) For The Induction Of Remission In Patients With Active, Mild To Moderate Ulcerative Colitis - Business Wire 01.14.13 | 07:01 pm
- Santarus And VeroScience Announce Publication Of New Analysis Of CYCLOSET (bromocriptine Mesylate) Cardiovascular Data In The Journal Of The American Heart Association - Business Wire 11.13.12 | 07:11 am
Partner Headlines for SNTS
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- Three Compelling Biopharma Stocks For 2013 - Seeking Alpha 12.26.12 | 09:12 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Santarus - Momentum - Zacks 07.18.12 | 01:07 am
- Verizon and 2 Stocks BREAKING 52-Week Highs - Wall St. Cheat Sheet 06.13.12 | 12:06 pm
- Most Volatile Stocks on Earnings Report Days - Seeking Alpha 01.07.11 | 07:01 pm
- UPDATE 1-Santarus files for approval of anti-swelling drug - Reuters 12.28.10 | 09:12 am
- Santarus' Q3 Loss: The Rough Path to Recovery - Seeking Alpha 11.09.10 | 09:11 am
